Thiotepa
From Anvita Health Wiki
Contents |
Introduction
- Tradenames: Tespa, Thioplex.
Indications
Contraindications
- severe myelosuppression
- pre-exsisting hepatic, renal or bone marrow damage
Dosage
- IV: 12-16 mg/m2 every 1-4 weeks
- intravesicular: 30-60 mg every 4 weeks
- intrathecal: 1-10 mg/m2 once to twice weekly
Pharmacokinetics
- extensively metabolized by the liver
- 1/2life 2-3 hours from plasma
- 1/2life 6-9 hours from CSF after intrathecal administration
- elimination via liver
- 1/2life = 2-3 hours
Adverse-effects
- common (> 10%)
-
- dose-limting toxicity
- severe thrombocytopenia (cumulative & dose-related)
- moderate to severe leukopenia
- pancytopenia may be fatal
- onset 7-10 days
- nadir 14 days
- recovery 28 days
- pain at site of injection
- less common (1-10%)
- hyperuricemia, dizziness, fever, headache, alopecia, rash, pruritis, stomatitis, hematuria, nausea/vomiting*
- uncommon (< 1%)
- alopecia, rash, dizziness, fever, tightness of the throat, anorexia, allergic reactions, hemorrhagic cystitis
- other
- mild nausea* ( emetic potential is low)
- phlebitis
- dysuria
- cystitis (rare)
- cognitive impairment (cumulative dose-related)
- secondary carcinogenesis
- drug adverse effects of alkylating agents
Drug-interactions
- succinylcholine: increased apnea with concurrent administration
- other alkylating agents & radiation therapy intensifies toxicity rather than enhances therapeutic benefits
Test-interactions
- increases serum K+
Mechanism-of-action
- alkylating agent
- interferes with DNA base-pairing
More General Terms
Internet Database
PubChem: 5453
References
- Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- Kaiser Permanente Northern California Regional Drug Formulary, 1998
